Engineering control in drug delivery

EpiQuil is developing dissolvable microneedle systems to explore approaches to consistent, controlled transdermal delivery of pharmaceutical compounds.

Contact Us

EpiQuil was founded on a simple belief: the way medicines are delivered can  shape the treatment experience.

We are dedicated to developing dissolvable microneedle systems intended for transdermal administration. Our development programs focus on addressing practical challenges in medication administration, guided by pharmaceutical quality principles and staged preclinical and clinical evaluation.

Drawing on experience in pharmacy, clinical research and medical technology, we collaborate with leading research groups to advance transdermal delivery systems from preclinical validation through clinical translation.

Our Company

About us

Our Vision

  • Person using a glass pipette in a laboratory with test tubes and glass containers.

    Precise

    Our R&D program is evaluating microneedle geometry, penetration characteristics, and formulation parameters to characterise performance drivers. Preclinical and ex vivo studies have been used to characterise microneedle–skin interaction and mechanical behavior as part of early proof-of-concept work.

  • A young woman with blonde hair, wearing a white face mask and white top, holds an hourglass with pink glass and white sand, with the sand flowing from the upper to the lower chamber.

    Controlled

    Our pharmaceutical development investigates dissolution profiles and permeation characteristics in ex vivo models following quality-by-design principles. This includes analytical method development focused on understanding release kinetics and a specifications strategy as the program advances.

  • Family of five sharing a moment outdoors, sitting on a wicker bench on a porch with lattice and greenery in the background

    Age-inclusive

    Design considerations include ease of application and user interaction across a broad range of potential users. Human-factors and usability-focused research is being undertaken to inform future development decisions and to support appropriate planning for any subsequent clinical evaluation.

Learn More
A person applying a patch to their upper arm.

Microneedle Technology

EpiQuil is developing dissolvable microneedle systems intended for transdermal drug-delivery applications under investigation.

Our R&D focuses on microneedle geometry, materials and formulation parameters, with the aim of supporting consistency and usability. Performance is being evaluated in preclinical models, and development is guided by pharmaceutical quality principles.

Our solution

‘‘Progress in science depends on new techniques, new discoveries, and new ideas, probably in that order.’’

— Sydney Brenner —